TY - JOUR
TI - Treatment of patients with multiple myeloma complicated by renal failure
with bortezomib-based regimens
AU - Roussou, Maria
AU - Kastritis, Efstathios
AU - Migkou, Magdalini and
AU - Psimenou, Erasmia
AU - Grapsa, Irini
AU - Matsouka, Charis and
AU - Barmparousi, Despina
AU - Terpos, Evangelos
AU - Dimopoulos, Meletios
AU - Athanasios
JO - Leukemia & Lymphoma
PY - 2008
VL - 49
TODO - 5
SP - 890-895
PB - TAYLOR & FRANCIS LTD LONDON
SN - 1042-8194, 1029-2403
TODO - 10.1080/10428190801930506
TODO - myeloma; renal failure; bortezomib
TODO - Renal failure is a common feature of multiple myeloma and a major
management problem. However there is limited data regarding the
reversibility of renal failure, the kinetics of serum creatinine and the
safety of novel agents such as bortezomib when administered to newly
diagnosed or relapsed/refractory patients with renal failure. Patients
and Methods. We evaluated 20 consecutive patients with newly diagnosed
or relapsed/refractory multiple myeloma and renal failure, defined as a
serum creatinine2 mg/dl. All patients received bortezomib with
dexamethasone or in combination with other agents (thalidomide,
doxorubicin or melphalan). Results. Reversal of renal failure was
documented in 40% of all patients and the median time to reversal was
17 days. Moreover 10 patients (50%) had 50% decrease in serum
creatinine and the median time to decrease was 35 days. Some decrease of
creatinine was documented in 85% of patients. The objective response
rate was 65%. Toxicities were similar to those seen in myeloma patients
without renal failure. Conclusions. Bortezomib based regimens can be
administered to myeloma patients with renal impairment and their
toxicity and efficacy are similar to those observed in patients without
renal impairment. Moreover, bortezomib-based regimens induce improvement
of serum creatinine in most patients and reversal of renal failure in
approximately one-third.
ER -